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Deve lopment of inhibitors of insul in-
regulated  aminopeptidase  (IRAP),  a  
membrane-bound z inc metal lopeptidase,  
is a promising approach for the  
discovery of drugs to treat memory loss  
such as that associated with  
Alzhe imer’s disease . There  is,  however,  
no consensus in the literature on  the  
mechanism by which inhibition occurs.  
Sequence alignments, secondary  
structure  predict ions and homology  
models based on the structures of  
recent ly determined re lated  
metallopeptidases suggest that  the  
extrace llular region consists of four  
domains. Partial proteolysis  and mass  
spectrometry have conf irmed some of  
the domain boundaries. We have  
produced purif ied  recombinant  
fragments of IRAP based on these data  
and examined their k inet ic and  
biochemical properties . Full length  
extrace llular constructs assemble as  
dimers which are not disrupted by  
reducing agents, metal chelators or  
inhibitor binding. Different fragments  
have the abi lity  to  d imerize suggesting  
an extended dimer interface. Only  
recombinant fragments containing the  
proposed domains 1 and 2 possess  
aminopept idase act ivity and bind the  
radiolabelled inhibitor, Ang IV.  
Fragments lacking domains 3 and 4  
possess reduced act ivity although they  
sti ll bound a range of inhibitors with  
the same aff in ity as longer length  
fragments.  In the  presence of Ang IV,  
IRAP is resistant to proteolysis  
suggest ing s ignificant conformat ional  
changes occur on binding of the  
inhibitor. We show that IRAP has a  
second Zn2+ b inding site, not  assoc iated  
with the catalytic region, which is lost  
upon binding Ang IV. Modulation of  
act ivity caused by domains 3 and 4 is  
consistent with a conformat ional change  
regulating access to the act ive s ite of  
IRAP.  
Insulin-regulated aminopeptidase (IRAP), also 
known as the AT4 receptor (1) or oxytocinase (2), 
plays a number of important but diverse roles in 
the body. While it was first implicated in the 
regulation of parturition through the proteolysis of 
the uterogenic peptide oxytocin, IRAP has 
subsequently been implicated in diabetes, the 
immune system and memory (3-5). IRAP is 
normally located in intracellular GLUT4 vesicles 
where it translocates to the plasma membrane in 
response to insulin. It is then rapidly internalized 
back into the post-endosomal GLUT4 vesicles (6). 
A range of ligands originally described as AT4 
agonists, including Angiotensin IV (Ang IV) and 
LVV-hemophin-7 (LVV-H7), have subsequently 
been shown to inhibit the aminopeptidase activity 
of IRAP (1,7,8). When administered intra-
cranially these inhibitors have been shown to 
greatly enhance memory and cognitive function in 
normal rodents (9,10) and reverse memory deficits 
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in animal models of amnesia (11-14). These 
effects are likely to be mediated through the 
inhibition of degradation of endogenous neural 
promnestic peptides since several IRAP substrates 
such as vasopressin (15,16), CCK-8 (17-22), 
oxytocin (23) and somatostatin (24,25) have been 
shown to facilitate learning and memory in animal 
models (see (26) for a review). A number of 
alternative mechanisms to explain the cognitive 
improvement have also been proposed (27). The 
importance of IRAP in memory has been 
strikingly demonstrated recently with the report of 
novel and highly specific small molecule 
inhibitors (28). When tested in vivo the 
compounds were able to improve cognitive 
function in animals. This work provides 
compelling evidence for the role of IRAP in 
improving cognitive function through inhibition of 
its enzymatic activity. 
IRAP belongs to the M1 family of zinc 
metallopeptidases (2). This class of enzymes is 
characterized by two common structural features: 
a Zn2+-binding motif HEXXH(X)18-E and an 
exopeptidase motif GXMEN. IRAP is a type II 
membrane-spanning protein with an extracellular 
catalytic site. The intracellular region contains 
many serines and threonines in phosphorylation 
consensus sequences while the extracellular region 
contains 18 N-linked glycosylation sites as well as 
a putative cleavage site (F154/A155) for release of 
the extracellular region of IRAP (29,30) with 
ADAM12 reported to be responsible for this 
cleavage (31). Several groups have looked at 
IRAP inhibition using a range of techniques and 
have proposed three different mechanisms of 
inhibition. Firstly, based upon the kinetics of 
inhibition, we have previously proposed that 
inhibitors such as Ang IV inhibit IRAP activity 
directly through competitive inhibition (7,32). 
Secondly, it has also been reported that Ang IV 
interacts with a juxta-membrane site of IRAP and 
that Ang IV may use an allosteric mechanism to 
modulate IRAP activity (33). Finally, it has been 
reported that Ang IV only binds with high affinity 
to the Zn2+-depleted apoenzyme and may inhibit 
IRAP activity by stabilizing an inactive 
apoenzyme form (34-36). While these conclusions 
are not necessarily mutually exclusive, it 
highlights that further work is required to 
understand the mechanism behind Ang IV 
modulation of IRAP activity. 
The extracellular portion of members of the 
M1 aminopeptidase family can be divided into two 
main sub-regions: an N-terminal region that 
contains the consensus active site residues and a 
C-terminal region of unknown function (37,38). It 
has been postulated that the C-terminal region acts 
as a molecular chaperone and is required for the 
correct processing and localization of the M1 
members, as truncations lacking this region are not 
processed correctly (38). While the C-terminal 
region in aminopeptidase A (APA) is not required 
for activity (38), Kumar et al. showed that small 
truncations of between 4-10 distal carboxyl 
terminal amino acid residues from two bacterial 
M1 aminopeptidases greatly reduced activity of 
the enzymes (39). Recently the structures of the 
aminopeptidase Tricorn Interacting Factor F3 and 
the related aminopeptidase N (APN) from E. coli 
and N. meningitides were determined (40-42). 
These structures suggested that the C-terminal 
region may play an important role in regulating 
activity, with an open conformation that can 
accept a substrate and a closed conformation that 
is likely to be catalytically active. It has also been 
shown that interactions between the two domains 
can alter activity (43). These results are suggestive 
of a potential role for the C-terminal region in 
regulating the activity of some M1 
aminopeptidases. 
Considering the wide-ranging effects mediated 
by IRAP and its inhibitors, an understanding of 
IRAPs biochemical mechanism of action and 
inhibition will help guide the design of more 
potent physiologically stable inhibitors. Here we 
define the essential regions of IRAP required for 
aminopeptidase activity, inhibition and regulation 
leading to a model that rationalizes these and 
previously published observations. 
 
Experimental Procedures 
 
Bioinformatics analyses- Sequence alignments of 
analogous and homologous sequences identified 
by psi-BLAST (44) were performed using 
ClustalW (45) and Fugue (46) and viewed using 
ALSCRIPT (47) and ESPRIPT (48). Secondary 
structure predictions were performed using a 
variety of programs including APSSP2 (49), JUFO 
(50), PHDSec (51), PRED-TMR2 (52), PsiPred 
(53) and SSpro (54). Potential transmembrane 
regions were predicted using HMMTOP (55), 
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PredictProtein, SOSUI (56), TMAP (57), 
TMHMM (58) and TMpred (59). A consensus 
result was recorded in each analysis where there 
was more than 70% agreement by all methods 
tested.  
Expression and purification- Seven different 
constructs covering the entire extracelluar region 
were expressed in insect cells, secreted into the 
media and purified as described in detail 
elsewhere (Ascher et al., in preparation). Briefly, 
the boundaries chosen were based upon 
bioinformatics analysis (Figs. 1 & S1) and 
expressed with His and MBP-His tags followed by 
a TEV protease site for removal of the tags. Site-
directed mutagenesis was performed using the 
Stratagene QuikChange II XL Site-Directed 
Mutagenesis Kit according to the manufacturer’s 
instructions. All constructs were sequenced by the 
Sequencing Facility, Pathology Department, 
University of Melbourne. Following baculoviral 
expression, the media was concentrated and buffer 
exchanged into 500 mM NaCl, 100 mM maltose, 
25 mM Tris-HCl, 20 mM imidazole pH 6.8-7.2, 
and batch purified using Qiagen Ni-NTA 
Superflow resin. The tags were removed from the 
constructs by incubation with recombinant His-
tagged TEV. The tags and tagged-TEV were then 
removed by incubation with Ni-NTA resin. The 
purified proteins were dialysed into 25 mM Tris-
HCl pH 6.8-7.2, 150 mM NaCl and concentrated. 
The individual domain constructs were also 
expressed with a GST tag for use in pull-down 
assays. The majority of these latter constructs were 
incorrectly processed; the fractions containing 
correctly secreted protein were purified by 
incubation with GSH resin from Novagen. A range 
of mutations were introduced into constructs 6 and 
7 (Fig. 1) using the QuickChange Site Directed 
Mutagenesis kit (Stratagene). 
Size exclusion chromatograph- The approximate 
molecular mass and oligmerization state of the 
purified proteins were estimated by size exclusion 
chromatography using a GE Akta Express fitted 
with a Sephedex 200 10/300HL column and using 
a mobile phase of 25 mM Tris-HCl pH 7.1, 150 
mM NaCl. Calibration was performed using the 
High MWt Calibration Kit from GE Healthcare (r2 
> 0.99). 
Dynamic light scattering- The oligmerization 
states of the purified constructs were analyzed by 
dynamic light scattering using a Malvern 
Instruments Zetasizer Nano ZS. The GE 
Healthcare High MWt Calibration Kit was used 
for standards.  
Pull-downs- For pull-down assays purified His-
tagged D1+D2 and GST-tagged D4 were bound to 
Ni-NTA and glutathione resin respectively. 
Unbound protein was washed off in 150 mM 
NaCl, 20 mM imidazole and 25 mM Tris-HCl pH 
7.2. The resins were then incubated at 4 ºC for 1-2 
hours with untagged D1+D2 or D4. As controls, 
untagged D1+D2 and D4 were also incubated with 
Ni-NTA and glutathione resin alone to ensure they 
did not interact directly with the resins (data not 
shown). Unbound protein was once again washed 
off in 150 mM NaCl, 20 mM imidazole and 25 
mM Tris pH 7.2, and the beads were resuspended 
in 1 x SDS protein sample buffer and analyzed on 
a 4-12% (w/v) acrylamide gel. 
Enzyme activity and inhibition assay- The catalytic 
activity of the recombinant products was 
determined by the hydrolysis of a synthetic 
fluorogenic substrate, L-leucine-4-
methylcoumaryl-7-amide (MCA), in a microtitre 
plate assay (as described in reference (60). The 
potency of each inhibitor was determined over a 
range of concentrations and at multiple substrate 
concentrations, with each concentration assayed in 
triplicate. The kcat and Km values were calculated 
using Michaelis-Menten kinetics by non-linear 
regression using the GraphPad Prism program 
(GraphPad Software Inc., San Diego, CA). The 
inhibition data were fitted by GraphPad Prism 
using non-linear regression to equations for 
competitive (Y=Vmax*X/(Kmapp+X)), non-
competitive (Y=Vmaxinh*X/(KM+X)), 
uncompetitive (Y=VmaxApp*X/(KmApp+X)) 
and mixed (Y= (Vmax * X)/(Kmapp 
+(X*(1+(I/(A*Ki)))))) inhibition models. The 
inhibition constants were also determined from the 
linear secondary plots (data not shown). The 
temperature stability of each construct was 
determined by incubating the purified protein at 
the temperature of interest (4-55 ºC) overnight. 
The activity was then measured as described 
above. The pH sensitivity of each construct was 
determined by dialyzing the purified protein into 
the pH of interest (pH 4-10) using Slide-A-Lyzer 
Mini Dialysis Units (Pierce) and the activity 
measured as described above. Each replicate (n) is 
a separate protein preparation measured in 
triplicate. All analyses were repeated a minimum 
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of three times (n=3). Significant differences were 
examined by one-way Anova with Tukey post-
test. 
Radioligand binding assay- The published method 
for determining competitive and saturation 
kinetics of IRAP (61) was modified to take 
account that this study has used purified protein 
rather than partially purified membrane 
preparations. Purified protein in 25 mM Tris-HCl 
pH 7.2, 150 mM NaCl was incubated with 125I-
Nle1-Ang IV (specific activity of 2175 Ci/mmol) 
in the presence of 100 µM 1,10-phenanthroline. 
For saturation binding studies up to 10 pmol of 
purified protein was incubated with increasing 
concentrations (up to 20 nM) of 125I-Nle1-Ang IV 
for 2 h at 37ºC and non-specific binding was 
determined in the presence of 10 µM of unlabelled 
Ang IV. For competition binding studies, 5 pmol 
of purified protein was incubated with 0.5 µCi/mL 
125I-Nle1-Ang IV and increasing concentrations of 
unlabelled Nle1-Ang IV and Ang IV for 2 h at 
37ºC. For both competition and saturation binding 
studies, bound and free radioligand were separated 
using illusra MicroSpin G-25 columns (GE 
Healthcare), pre-equilibrated in the binding buffer. 
The radioligand binding data was analyzed on an 
iterative, model-fitting program on GraphPad 
Prism (GraphPad Software Inc., San Diego, CA, 
USA) with Kd and Bmax derived using the equation 
Y = Bmax*X/(Kd + X) and Ki derived using the 
equation Ki = IC50 /(1 + [S]/Kd). Each replicate (n) 
is a separate protein preparation measured in 
triplicate. All analyses were repeated a minimum 
of three times (n=3) and significant differences 
were examined by one-way Anova with Tukey 
post-hoc test. 
Proteolytic fragmentation- Protease digestions by 
proteinase K, chymotrypsin and trypsin were 
conducted in 50 mM Tris–HCl buffer pH 7.2, 
containing 150 mM NaCl in the presence and 
absence of 500 nM Ang IV at 37ºC for 2 hours. 
The reactions were stopped by either the addition 
of sample loading buffer and boiling for 5 min 
prior to analysis by SDS/PAGE or by the addition 
of PMSF to a final concentration of 0.5 mM for 
proteinase K and chymotrypsin digests or soybean 
trypsin inhibitor for trypsin digests. 
ESI-MS and TOF-MS- Proteolyzed fragments, 
obtained by partial trypsin proteolysis, were 
deglycosylated using PNGaseF in order to obtain 
adequate sequence coverage. The Sigma-Aldrich 
Trypsin Profile IGD Kit was then used to generate 
tryptic peptides for MS analysis. Samples were run 
on an Agilent 6510 Q-TOF LC/MS using a C18 
column to help separate peptides and an Agilent 
6340 Ion Trap LC/MS using an Agilent HPLC 
chip (40 nl enrichment column, 150 mm x 75 µm 
analytical column with 5 µm C18 Zorbax resin). 
Experimental peptide masses and ms/ms 
fragmentation were then compared to the predicted 
peptide masses by the Expasy webtool 
PeptideMass (http://au.expasy.org/tools/peptide-
mass.html, (62)). 
Inductively coupled plasma mass spectrometry 
(ICP-MS) for analysis of metal content- Samples 
(200 µg) were incubated, with and without Ang IV 
(0, 100, 250, 500 and 1000 nM), at room 
temperature for one hour (for comparisons only 0 
and 250 nM data are presented). The protein was 
then isolated by running through an Illusra 
MicroSpin G-25 column (GE Healthcare), pre-
equilibrated in the sample buffer, and then 
concentrated. Samples (at 1 mg/ml) were diluted 
in a 1% (v/v) HNO3 solution for analysis by ICP-
MS. ICP-MS was performed using an Ultramass 
700 instrument (Varian, Victoria, Australia). 
Levels of Fe and Cu ions measured were not 
significant in any of the samples tested. Each 
replicate is of a different protein preparation and 
significant differences were analyzed by one-way 
Anova with Tukey post-test. 
Molecular modeling of IRAP- The crystal 
structures of two closely related M1 
aminopeptidases have been determined: 
Thermoplasma acidophilum Tricorn Interacting 
Factor F3 (PBD code 1Z5H, (40)), and 
Escherichia coli aminopeptidase N (APN) (PBD 
code 2DQ6, (41)). Whilst the overall similarity 
between the sequences is low (ranging between 21 
and 25% pairwise sequence identity, 38-46% 
sequence similarity to IRAP), the region 
immediately surrounding the active site residues, 
including the HEXXH and GXMEN motifs, is 
relatively well conserved (23-35% pairwise 
sequence identity, 42-55% sequence similarity to 
IRAP) and some significant sequence similarity 
can be seen in the C-terminal regions (eg. ~33% 
similarity between Tricorn vs IRAP). A sequence 
alignment of several different members of the M1 
aminopeptidase family along with predicted 
secondary structure was used to guide model 
building (Fig. S1). The models (open and closed 
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states) were built using Swiss PDB Viewer (63) 
and minimized in Sybyl under the Tripos 
forcefield (Tripos, St. Louis, MO). Zn2+ was 
manually added to the active site motif after 
comparison with the Zn2+-bound structures of 
aminopeptidase N and Tricorn Interacting Factor 
F3 indicated the conformation of residues in the 
Zn2+ binding motif was identical amongst the 
proteins. The quality of the models were analyzed 
with Verify3D (64) which indicated that the 
models were of good quality (data not shown).  
Statistical analyses- All statistical analyses were 
performed using using the GraphPad Prism 
program (GraphPad Software Inc., San Diego, 
CA). Each replicate is of a separate protein 
preparation measured three times. 
 
RESULTS 
 
Design of constructs.  We predicted that IRAP 
is composed of six distinct regions based upon 
sequence alignments, domain and secondary 
structure prediction programs (Figs. 1B & S1): a 
cytoplasmic region (residues 1-110), a typical α-
helical trans-membrane region (TM, residues 111-
133) followed by a small juxtamembrane region 
(JxM) of undefined structure, a β-sheet region 
(D1, 171-365) and two α-helical regions (D2, 
residues 365-615 and D4, residues 704-1025) 
separated by another β-sheet region (D3, 615-704). 
D1+D2 constitute the catalytic domains which 
contain the HEXXH(X)18E Zn2+ binding motif and 
the GAMEN exopeptidase motif. Eight distinct 
constructs were designed based upon this 
breakdown (Fig. 1). These were successfully 
expressed in insect cells, using baculovirus, and all 
extracellular constructs were efficiently secreted 
into the media, in contrast to work on related 
enzymes in mammalian cells. 
The crystal structures of three related zinc 
aminopeptidases have been determined: LTA4H 
(65), Tricorn Interacting Factor F3 (40) and APN 
(41,42). Based upon these structures we have 
generated several molecular models of the 
extracellular region of IRAP. Initially we had built 
a model of the catalytic region on the crystal 
structure of LTA4H (28,66). At the time the C-
terminal region could not be modelled due to very 
low sequence similarity: sequence alignments 
suggested that LTA4H lacked D3 and a significant 
proportion of D4. Following the publication of the 
crystal structures of Tricorn Interacting Factor F3 
and E. coli APN we were able to model the entire 
extracellular region of IRAP in open and closed 
states (Figs. 1B & C). While the secondary 
structural alignment between these two 
extracellular region models was consistent, the 
relative positioning of the individual domains was 
quite distinct. The models of the extracellular 
region of IRAP are limited by the fact the 
sequence similarity and hence reliability of the 
model decreases towards the C-terminal end of the 
molecule. Regardless, the homology models are 
consistent with the bioinformatics predictions of 
the different structural regions (D1-D4). All the 
models suggest that D1 and D2 form a tight 
interface while D3 and D4 form more distinct 
independent units. 
IRAP extracellular region dimerizes and is 
comprised of separable stable domains.  The 
purified constructs were analyzed by size 
exclusion chromatography (SEC) and dynamic 
light scattering, under native non-reducing 
conditions. The full length constructs eluted in a 
nearly homogeneous peak with a molecular weight 
consistent with a dimerized species of the 
recombinant IRAP (Table 1). Homodimer 
formation is one of the characteristic features of 
several membrane-bound members of the M1 
family including APA (37), thyrotropin-releasing 
hormone-degrading ectoenzyme (TRH-DE) (67) 
and APN (68,69). APA and TRH-DE form 
disulfide-linked homodimers in which the first 
cysteine residue in the extracellular region after 
the transmembrane domain is covalently bound to 
the same cysteine in the second monomer of the 
dimer. Therefore, we hypothesized that this might 
also be the case for IRAP. However the 
recombinant IRAP was completely dimerized even 
in the presence of 5 mM DTT and also in 
constructs lacking the key cysteine residues 
(Cys134 and Cys141). This indicated that inter-
molecule disulfide formation is not required for 
dimerization of IRAP. To examine whether an 
inter-molecular disulfide is present, the purified 
constructs were run on SDS-PAGE in the presence 
and absence of DTT. For all purified extracellular 
constructs, a weak band with a molecular weight 
consistent with a dimer of IRAP was always 
observed. A difference between the samples run in 
the presence and absence of DTT was only 
observed in the constructs containing the juxta-
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membrane region (which contains C134 and 
C141), where in the absence of DTT a higher 
percentage of dimerized product was observed 
(data not shown). This disulfide, although not 
necessary for dimerization, is in a similar position 
to those in APA and TRH-DE where it is 
important for dimerization.  
To examine any effect that binding of 
inhibitors may have on IRAP’s dimerization, with 
potential implications for intracellular signaling, 
SEC was run in the presence of Ang IV. However, 
no differences were observed. As Ang IV has been 
proposed to only bind to the apo-form of IRAP 
(34,35,70,71), the effects of the metal chelator 
1,10-phenanthroline were also examined in the 
presence and absence of Ang IV. Once again the 
extracellular regions were predominantly dimers 
in the presence of 1,10-phenanthroline, with or 
without Ang IV.  
D1+D2 and D4 formed homodimers 
independently of each other (Table 1), though a 
higher proportion of monomer was observed for 
the separate domains than observed with the full 
length construct. Thus D1+D2 and D4 appear to 
contain sufficient information on their own for 
homodimerization, suggesting an extended dimer 
interface between IRAP molecules.  
When expressed for an extended period of 
time the His-tagged full length extracellular 
constructs were degraded in insect cell media to a 
stable protein approximately half the size of the 
full length construct. This fragment still contained 
its hexameric His tag, indicating that proteolysis 
was removing part of the C-terminal end of the 
protein. These observations were further explored 
by subjecting purified full length constructs to a 
range of proteolytic enzymes, which repeatedly 
showed that partial proteolysis yielded two stable 
fragments, one containing a His tag and the other 
without (Fig. S2). The boundaries of these stable 
fragments were examined by mass spectroscopy of 
in-gel tryptic digested peptides which suggested 
that the fragments corresponded to residues 168 to 
560 and 718 to 1016 (Table S1). While tryptic 
peptides from the D3 region could be observed in 
the full length construct, they were not observed in 
the partially proteolyzed fragments suggesting that 
the His-tagged fragment corresponded to D1+D2 
and the other fragment corresponded to D4. This 
proteolyzed protein, purified using the His-tag at 
the N-terminus, was more temperature and 
proteolytically stable than the catalytic domain 
construct containing D3 and was shown to also run 
as a dimer on SEC (Table 1).  
Interaction between catalytic and C-terminal 
domains.  There was some evidence of 
heterodimer formation, as judged by SEC, when 
purified D1+D2 and D4 fragments were mixed 
together. A small amount of a higher order 
complex was also evident by both SEC and 
commassie stain, consistent with a heterotetramer 
forming consisting of two D1+2 and two D4 
fragments. Pull-down experiments were carried 
out to further analyze and characterize these 
complexes. Purified, untagged D1+D2 and D4 
proteins were mixed with the equivalent His-
tagged proteins over the IMAC resin and the 
isolated proteins analyzed by SDS-PAGE. The 
hexa-His-tagged D1+D2 constructs were able to 
pull down purified untagged D1+D2 and D4 
while, conversely, the GST-tagged D4 was able to 
pull down purified untagged D1+D2 and D4 (Fig. 
S2). 
When partial proteolysis was performed in the 
presence of Ang IV, the intact extracellular region 
construct was resistant to proteolysis with less 
than 50% breakdown after 90 min compared to 
nearly complete proteolysis over the same time 
period in the absence of ligand. This is consistent 
with the hypothesis that upon binding of Ang IV 
the extracellular region of IRAP undergoes a 
conformational change making it less susceptible 
to proteolysis.  
Catalytic domain is sufficient for catalytic 
activity and Ang IV inhibition.  We predicted that 
D1+D2 alone would contain all of the structural 
information necessary for activity, based upon 
sequence comparisons to other M1 
aminopeptidases (Fig. S1), and thus all constructs 
containing D1+D2 should be active. Our data 
confirmed this hypothesis but also revealed that 
the specific activity of D2 was significantly lower 
than the entire extracellular region (Table 2). The 
Km values for the synthetic substrate MCA of the 
full length extracellular region and D1+D2 alone 
were similar to previously reported values for 
partially purified IRAP preparations (7) indicating 
that they show approximately the same level of 
affinity for the substrate. The Vmax of purified 
D1+D2, whether expressed individually or in the 
presence of D4, was significantly reduced in 
comparison to the full length construct. This 
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suggests that the decrease in activity observed for 
the catalytic region alone is not due to an altered 
affinity for the substrate but rather is due to the 
catalytic rate. This could indicate a requirement 
for D4 for full activity (ie. D4 acts as an 
activator/regulator) or that a proportion of the 
population is inactive. The ligand binding Bmax 
for D1-2 (Table 1) is similar to the complete 
extracellular domain, demonstrating that the 
reduced enzyme activity of D1-2 is not due to a 
proportion of this construct being unfolded. 
D1+D2 was also much more temperature and pH 
sensitive than the entire extracellular region (data 
not shown).  
The role of D4 in regulating the activity of 
IRAP was explored further by measuring the 
activity of D1+2 in the presence of D4. A small 
increase in the activity of D1+D2 was observed in 
the presence of D4, although not to the level found 
for the entire extracellular region construct (Table 
2). This may be because of low stability of the 
D1+D2 and D4 hetero-dimer or the interaction of 
the domains as separate molecules being only a 
partial mimic of the intact protein. This suggests 
that D4 is required for increasing the stabilization 
and activity of D1+D2 and is consistent with the 
hypothesis that a conformational change of D4 
upon binding of substrate may be involved in 
regulating the activity of D1+D2.  
A surprising observation was that the presence 
of DTT substantially enhanced the activity of the 
full length extracellular constructs (Table 2) with 
Vmax only slightly increased but a substantially 
lower Km for the synthetic substrate MCA. This 
suggested that DTT was acting by increasing the 
affinity for the substrate rather than enhancing the 
rate of the reaction. By contrast this phenomenon 
could not be detected with the catalytic domain 
constructs indicating that the enhanced affinity 
seen in the presence of DTT required D3 and D4. 
An alternative reducing agent, 2-mercaptoethanol, 
was tested to clarify whether it is the reducing 
action of DTT that enhances the activity of the full 
length constructs. 2-Mercaptoethanol was able to 
increase the affinity of the full length extracellular 
constructs for MCA, though not to the same extent 
as DTT (data not shown). This weaker effect could 
be a result of DTT’s additional metal chelation 
enhancing affinity or differences in their reducing 
properties, however it does suggest that the 
presence of a reducing agent does improve the 
affinity of IRAP for MCA, potentially through the 
disruption of an internal disulfide bond enhancing 
access of substrate to catalytic site. Analysis of the 
metal content of the full length constructs in the 
presence and absence of DTT or 2-
mercaptoethanol revealed the same Zn2+ ion 
content.  
The entire extracellular region of IRAP was 
inhibited by both Ang IV and LVV-H7, giving 
Ki’s consistent with previously published values 
(Table 2) (7). Several of the constructs were 
designed to lack the juxta-membrane region 
previously proposed as the allosteric site 
responsible for inhibition (constructs 3 and 8) (33). 
Inhibition of these constructs, however, was 
observed to approximately the same order of 
magnitude as seen with the entire extracellular 
region (Table 2). This suggests that any allosteric 
binding site for Ang IV outside of D2 of IRAP is 
not important for inhibition. Kinetic modelling 
showed that, consistent with our previously 
published observations (7), Ang IV competitively 
inhibited the activity of both the full length 
extracellular region and the catalytic region (R2= 
0.98) (data not shown). 
We found that Ang IV only binds to constructs 
containing D1+2 as judged by binding of 125I-
labeled Nle1-Ang IV to each of the constructs 
(Table 1), consistent with our kinetic data showing 
that Ang IV is binding directly to the catalytic site. 
Specific binding of radioligand was only observed 
in the presence of chelator, as has previously been 
reported, leading to the conclusion that Ang IV 
only binds with high affinity to the apoenzyme 
(34-36). The presence of DTT was, however, able 
to improve the binding efficiency (by 
approximately 200%) of the full length constructs 
but not the catalytic constructs (Fig 2B). To rule 
out any effect of iodination upon the binding 
properties of Ang IV, the ability of 125I-labeled 
Nle1-Ang IV to inhibit the catalytic activity of 
IRAP was examined. The iodinated Nle1-Ang IV 
did not show any significant difference in 
inhibition to the unlabeled Nle1-Ang IV. This does 
not necessarily indicate that Ang IV only binds to 
the apoenzyme but that we can only measure 
binding to the apoenzyme. This could be a 
reflection of different mechanisms of binding, that 
the removal of zinc is able to help further stabilize 
Ang IV binding and/or differences in binding 
affinity between the native (approx 100 nM) and 
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apoenzyme (approx 10 nM) particularly as weaker 
affinity binding can easily be missed by 
radioligand binding experiments. Analysis of the 
binding curves showed no indication of 
cooperativity between the two monomers, with the 
caveat that the measurements were done in the 
absence of Zn2+ and so are not necessarily carried 
out under native conditions. 
Identification of a second non-catalytic zinc 
site.  ICP-MS was used to examine the Zn content 
in the purified protein and indicated that there 
were 2 Zn2+ ions per monomer in the full length 
extracellular construct (Table 1). This was 
surprising as only one Zn binding site had been 
previously identified (72). It is likely, however, 
that the second site was missed because there is no 
second consensus zinc binding sequence and, 
unlike here, the protein was expressed and purified 
without the addition of Zn2+ (72). The results 
reported by Matsumoto and colleagues (72) 
indicate that they may actually have had partial 
occupancy at this second site, as they obtained a 
ratio of 1.3 molecules of Zn2+ per monomer of 
IRAP. The models of IRAP were then uploaded to 
the Stanford Feature Metal Scan analysis model 
(73) that correctly identified the catalytic zinc 
binding site in the models of both the open and 
closed form, and predicted another potential zinc 
binding site towards the C-terminus of the open 
model, with two potential sets of co-ordinating 
residues consisting of E825, C828 and C835; and 
H830, H934 and H938.  
Examination of individual domain fragments 
indicated that one Zn2+ was associated with 
Domain 1 and 2 and the other with Domain 4, 
consistent with the Feature Metal Scan prediction. 
Upon the addition of excess Ang IV to the full 
length extracellular constructs one Zn2+ was lost. 
This was particularly interesting in light of 
Demaegdt et al, (34-36), and as we have shown 
here, who proposed that Ang IV only binds with 
high affinity to an IRAP apoenzyme lacking the 
catalytic Zn2+ ion. Loss of zinc, however, was not 
observed when Ang IV was added to the catalytic 
domain constructs (Table 1) suggesting that it is 
the Zn2+ associated with Domain 4 that was lost, 
consistent with the hypothesis that Domain 4 
undergoes a conformational change following 
binding of the peptide inhibitor. The effect on zinc 
binding of other IRAP ligands and substrates was 
also explored. While not as marked as with Ang 
IV, a reduction of 75% of the second Zn2+ ion was 
observed for the full length extracellular constructs 
upon the addition of excess MCA, oxytocin and 
vasopressin, but no loss of zinc was seen from the 
catalytic domain constructs (data not shown). 
To further explore this novel Zn2+ binding site, 
the pH dependence of Zn2+ binding by the purified 
constructs was examined. This revealed that the 
two sites had similar profiles, with all zinc lost at 
approximately pH of 6.2; approximately the 
normal pKa of histidine residues (Fig. 3A). This 
correlated with the pH sensitivity of the activity of 
the constructs as all enzyme function was lost 
around pH 6.2. While the catalytic Zn2+ binding 
motif has been well characterized and is known to 
contain two histidines, these data suggest that 
histidine residues are also involved in the 
chelation of the second zinc as well. Therefore, to 
identify some of the residues that are important in 
this second Zn2+ binding site we mutated all 
histidine residues to alanines, expressed and 
purified them from insect cells for biochemical 
analysis (Table S2). Six of the purified histidine 
mutated constructs showed significant changes in 
zinc content, His464Ala, His468Ala, H830Ala, 
His934Ala, His938Ala and His979Ala. Histidines 
464 and 468 are the ‘catalytic histidines’ 
responsible for coordinating the zinc ion in the 
active site and have both been characterized 
previously (74). Consistent with their role in the 
active site, and the previous characterization of 
their mutation, the His464Ala and His468Ala both 
lacked any measurable aminopeptidase activity 
(Fig. 3B & Table S2). The other four histidine 
mutations are clustered towards the distal end of 
Domain 4 (Fig. 3C). Inspection of both models of 
IRAP identified that this cluster of histidines could 
potentially bind a Zn2+ ion with coordinating 
ligands of H830, H934 and H938 or H934, H938 
and H979. We consider the former more plausible, 
since it is consistent with the predictions from the 
Stanford Feature Metal Scan and the H979A 
mutation only resulted in a partial reduction in 
zinc binding, potentially though a localised 
allosteric affect. Mutations in any of these four 
decreased the amount of zinc bound, but did not 
dramatically alter the aminopeptidase activity.  
 
DISCUSSION 
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In nearly all studies to date characterization of 
IRAP has been carried out on partially purified 
preparations from mammalian cells requiring 
membrane micelles for solubilization. The one 
notable exception is a study by Matsumoto and 
colleagues who purified a soluble form and 
showed that the full length extracellular region 
was able to dimerize and bind zinc in an 
approximately 1:1 stoichiometric ratio (72). In this 
work we have used insect cells to express a range 
of soluble recombinant IRAP truncations and 
mutants enabling a more detailed characterization 
of the enzyme, particularly with regards to 
behavior of the peptide inhibitor Ang IV. Ang IV 
has previously been shown to competitively inhibit 
IRAP’s aminopeptidase activity with high 
nanomolar efficacy, although at levels much 
higher than the localized concentrations present in 
the brain. In addition radiolabelled Ang IV had 
only been shown to bind to IRAP, with low 
nanomolar efficacy, in the presence of metal 
chelators (36). These studies have led to 
questioning whether IRAP is the AT4 receptor 
responsible for the memory enhancing effects of 
Ang IV, particularly in light of recent in vivo 
studies attributing the memory enhancing effects 
to either aminopeptidase N, the AT1 receptor or c-
MET (75-77). One potential explanation for the 
requirement of metal chelators in the radioligand 
binding studies has been their protease inhibitory 
effects preventing the degradation of Ang IV in 
the partially purified membrane preparations. Thus 
studies of highly purified IRAP fragments could 
shed light on some of these questions.   
All constructs containing the full length 
extracellular region were active and showed a 
similar affinity to Leu-MCA as previously 
published (66,72). This provided reassurance that 
not only was the recombinant protein produced in 
the insect cell system active and behaving nearly 
identically to that produced from mammalian 
systems, but that the use of partially purified 
membrane preparations was a reliable way of 
analyzing IRAP activity. Furthermore, they were 
all inhibited by amastatin, bestatin, Ang IV and 
LVV-H7 to a similar extent to what had been 
previously published using partially purified 
membrane preparations. All these inhibitors were 
competitive, consistent with our previously 
published results using partially purified 
membrane preparations (7,32).  
A major finding here is that the catalytic 
region by itself (D1+D2) is sufficient for both 
activity and inhibition by natural peptide 
antagonists. This is in contrast to work on APA, 
where it was shown that the C-terminal region was 
required for correct processing and activation of 
the catalytic region (38). Activity of the catalytic 
regions, however, was dramatically lower than for 
the full extracellular constructs, suggesting that the 
C-terminal region is still required for full activity. 
This is consistent with the work of Kumar and 
colleagues (39) who showed that removal of just a 
few amino acid residues from the C-terminal 
region of the bacterial M1 aminopeptidases 
Tricorn interacting factor F2 and Peptidase N 
greatly reduced activity. When co-expressed and 
purified with the C-terminal region, or the activity 
measured in the presence of the C-terminal region, 
the catalytic constricts did show enhanced activity, 
although still not to the levels of the full length 
construct. We saw the same levels of both activity 
and inhibition by Ang IV in the presence and 
absence of the juxta-membrane region proposed as 
the binding site of Ang IV (33). This suggests that 
allosteric binding by Ang IV to a juxtamembrane 
region does not contribute to inhibition of IRAP. 
Furthermore, 125I-Ang IV was shown to bind in an 
approximately 1:1 ratio to all of the constructs 
containing the catalytic region, suggesting that 
there is only one Ang IV binding site and it is not 
located in the juxta-membrane region or in the C-
terminal region. This is consistent with the kinetic 
modeling that indicated Ang IV inhibition was 
competitive. However, as has been previously 
reported, we only observed Ang IV binding in the 
presence of divalent cation chelators. 
Two members of the M1 family, APA and 
TRH-DE, have been shown to exist as disulfide-
linked homodimers and for both enzymes the 
cysteine residue adjacent to the transmembrane 
domain was identified as the amino acid involved 
in the covalent bond (37,67). In contrast, APN 
predominantly exists as a non-covalently-linked 
homodimer although the available crystal 
structures are of monomeric forms (68,69). A 
number of studies have proposed that IRAP also 
exists as a homodimer (72,78) and in the present 
study we have demonstrated that IRAP exists as a 
non-covalent homodimer by two different 
methods. While both the N-terminal and C-
terminal regions formed dimers by themselves; 
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this does not clearly explain the role of either 
region for dimerization in the native enzyme 
which will only be elucidated by obtaining a 
crystal structure for the intact extracellular 
domain. The functional importance of 
homodimerization (due to non-covalent 
interactions) for correct trafficking, processing, 
catalytic activity and signaling remains to be 
elucidated.  
Limited proteolysis of the full length 
extracellular constructs revealed the formation of 
two stable proteins, one corresponding to Domain 
1 and 2 and the other to Domain 4. However, 
neither of these fragments contained the interstitial 
β-sheet region (Domain 3). In the presence of Ang 
IV the full length constructs were significantly 
more resilient to proteolysis, consistent with the 
proposal that the two regions undergo a 
conformational change upon binding 
substrate/inhibitor. Because labeled Ang IV only 
bound in the presence of metal chelators, we also 
tested the proteolytic sensitivity of the full length 
constructs in the presence of 1,10-phenanthroline. 
Limited proteolysis resulted in the formation of 
two protein fragments irrespective of whether the 
metal chelator was present or not. However the 
addition of Ang IV did not reduce the sensitivity 
of IRAP to proteolysis in the presence of metal 
chelator. This suggests that Ang IV is binding in a 
different way in the presence of metal chelators 
and could explain the differences observed 
between the binding affinities and inhibition 
constants. 
We observed that the presence of DTT not 
only increased affinity of the full extracellular 
region for 125I-Ang IV but also the activity 
measured by hydrolysis of MCA as well. This 
confirms a previous observation by Jarvis and 
colleagues (79). Previously metal ion modulation 
of IRAP has been shown to be important in both 
activity and Ang IV binding (34,70). Therefore we 
considered that one possible explanation was that 
DTT might be chelating away metal ions in a 
similar manner to EDTA, thus increasing the 
affinity of IRAP for MCA and Ang IV. This 
would be consistent with other studies that have 
demonstrated an important role for metal ions in 
APA and APN activity (80-82). However, we 
showed that the bound zinc is not affected by 
addition of DTT and there are no are obvious ions 
in the IRAP preparation that might be chelated by 
the reducing agent. We also noted that 2-
mercaptoethanol resulted in an increase in binding 
affinity and activity, though not to the same extent 
as with DTT. An interesting hypothesis is that the 
redox state may play a role in the regulation of 
activity, with reduction in the GLUT4 post-
endosomal vesicles promoting maximal activity, 
which is lost over time while IRAP is on the cell 
surface in an oxidizing environment. This suggests 
that the compartment for maximal IRAP activity is 
intracellular, which may reflect its role in 
intracellular vesicles processing MHC class 1 
antigens (3,4). It also suggests that IRAP activity, 
and the related conformational changes, may play 
a role in trafficking, consistent with the signaling 
hypothesis of Ang IV memory enhancement (83). 
The open model of IRAP suggests that C828 and 
C835 could form a disulfide bond formation 
whereas such a bond is not possible in the closed 
model. This is consistent with DTT promoting 
conversion of the open state to the closed, active 
state. 
Other groups have attempted to examine the 
role of the catalytic region of M1 aminopeptidases 
in isolation by expressing just the catalytic region 
in mammalian cells although they have not been 
able to observe activity (38,84). Recently, 
however, it has been observed that the catalytic 
regions show some activity following either 
proteolysis of the intact aminopeptidases to 
generate the catalytic region or co-expression with 
the C-terminal region (38,85). This suggests that 
the C-terminal region is essential for correct 
processing and folding in mammalian cells. By 
using baculovirus we have been able to overcome 
the requirement for the presence of the C-terminal 
region and have been able to express and purify 
the catalytic region of IRAP by itself and have 
observed proteolytic activity. Based on recent 
crystal structures it was proposed that 
conformational changes of the C-terminal region 
of APN might regulate activity (41) where the 
extracellular region might adopt an ‘open’ and 
‘closed’ conformation with the C-terminal region 
pivoting on a ‘hinge’. As part of the mechanism of 
moving from an ‘open’ to ‘closed’ conformation 
Ito and coworkers (41) proposed that a small 
movement of catalytic residues occurred, 
generating a catalytically competent active site. In 
support of this, removal of just a few residues 
from the C-terminus of a couple of different M1 
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aminopeptidases greatly reduced their activity 
(39). This may help explain the dramatically 
reduced activity of the catalytic region by itself, as 
it may require the conformational changes induced 
by the C-terminal region for full activity. The 
observation that DTT was able to enhance activity 
and Ang IV binding only in the presence of the C-
terminus may be a result of this interaction 
between the C-terminus and active site, as the 
effect was not observed on the catalytic region by 
itself. In support of the hypothesis that large 
conformational changes occur between the 
domains the full length extracellular construct was 
significantly more resilient to proteolysis in the 
presence of Ang IV. 
When we examined the Zn2+ content in our 
purified extracellular region constructs we were 
surprised to find two Zn2+ bound per monomer, as 
it had been previously widely accepted that there 
was only one Zn2+ binding site. Analysis of our 
range of constructs revealed that the individual 
catalytic regions contained one Zn2+ per monomer, 
consistent with the consensus Zn2+ binding motif at 
the active site. We were further surprised that 
constructs containing the isolated C-terminal 
region also contained approximately one Zn2+ per 
monomer, particularly as there is no consensus 
Zn2+ binding motif, based on sequence analysis, 
nor has this second site been reported for any other 
M1 aminopeptidase before. In silico scanning of 
the models of IRAP revealed two potential 
coordination clusters, although these were only 
present in the model of the open form. One cluster 
consisted of cysteine 828 and 835, mentioned 
above. While this could provide a link between the 
regulatory effects of reducing agents in the 
presence of D4 and the changes in zinc binding in 
D4, this is unlikely since both were observed in 
the open sate, not the closed state. Mutation of His 
residues indicated the likely binding site for this 
second zinc was towards the distal end of Domain 
4, with coordinating residues of H830, H934 and 
H938, although it was not needed for activity or 
substrate specificity. It is not clear whether this 
second site is a biologically relevant Zn binding 
site, although for the purposes of this study it 
proved a useful reporter. This study did reveal 
changes occurring in Domain 4 during binding. 
Interestingly, in the presence of Ang IV this 
second zinc ion is lost. This is further evidence 
suggesting that upon the binding of Ang IV, IRAP 
undergoes a conformational change. This is 
consistent with our partial proteolysis results 
showing that the extracellular constructs were 
more protease resistant in the presence of Ang IV, 
whereas in the absence of the inhibitor the 
constructs were readily degraded to separate N-
terminal and C-terminal products. The proteolytic 
fragmentation was similar to that seen in APA by 
Hesp and Hooper (37) and thus consistent with a 
common domain structure for the M1 
aminopeptidases. There have been reports of other 
bivalent metal ions regulating the activity of M1 
aminopeptidases including calcium in APA 
(86,87), magnesium and calcium in IRAP and 
APN (34,70,82), although none of these metals 
would be expected to bind to histidine residues. 
The results presented in this work support the 
hypothesis that conformational changes allow the 
extracellular region of IRAP to adopt an ‘open’ or 
‘closed’ conformation. The presence or absence of 
divalent metal ions appears to play a role in 
regulating these states. In the absence of Domain 4 
these conformational changes are limited and 
result in greatly reduced activity consistent with 
Domain 4 being involved in the regulation of 
enzymatic activity. 
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acid; GLUT4, Glucose transporter 4; HBM, honey bee melettin; ICP-MS, Inductively Coupled 
Plasma Mass Spectrometry; IMAC, immobilized metal affinity chromatography; IRAP, Insulin-
regulated membrane aminopeptidase; L-RAP, Leukocyte-derived arginine aminopeptidase; 
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chromatography; TEV, tobacco etch virus; TOF-MS, time of flight mass-spectrometry; TRH-DE, 
thyrotropin-releasing hormone degrading enzyme 
 
 
FIGURE LEGENDS 
 
Fig. 1. IRAP domain structure. (A) Schematic diagram of the proposed domain boundaries 
and the different constructs expressed in insect cells. (B and C) Ribbon representation of the 
homology models of the extracellular region of IRAP based upon the crystal structures of Tricorn 
Interacting Factor F3 and APN respectively. Panel B is a putative model of the open state and 
Panel C the closed state of IRAP. The models are colored according to putative domains using the 
same coloring scheme as shown in panel A. The N and C termini are labeled, and the 
approximate location of the active site is donated by a star. 
 
Fig. 2. Kinetic and binding curves. (A) Saturation binding of 125I-Nle1-Ang IV to construct 7 
(F/A, D1-4) at three different protein concentrations. (B) Competitive binding of Ang IV in the 
presence and absence of 1 mM DTT (▼ and ○ respectively) and Nle1-Ang IV (▲) to constructs 7 
(F/A, D1-4; Panel B) and 3 (D1-2; Panel C). (D) Aminopeptidase activity of the purified 
constructs measured by following Leu-MCA degradation. (E) Inhibition of the aminopeptidase 
activity of construct 3 (D1-2) by Ang IV, concentration in nM shown for each symbol. 
 
Fig. 3. Second zinc binding site. (A) pH dependence of activity and zinc binding (shown here 
construct 6 (JxM,D1-4)) suggest a role for histidine residues in both IRAP metal binding sites. 
(n=3). (B) Aminopeptidase activity of the histidine mutants measured by following Leu-MCA 
degradation. (C and D) Proposed allosteric zinc binding site in Domain 4 with putative 
ligands, from left to right, His 830, His 934, His 938 and His 979 highlighted in purple. 
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Table 1 Biochemical Properties of Fragments  
 
ICP-MS 
(n = 3) 
Radioligand 
Saturation Binding 
(n = 3 at 3 different 
protein 
concentrations) 
Radioligand 
Competitive Binding 
(n = 3) 
Construct 
Number 
(domains) 
Oligmeriz
ation 
n = 2 
Zn 
content 
(moles 
zinc per 
mole 
protein) 
 
Zn content 
(moles zinc 
per mole 
monomer) 
in presence 
of Ang IV 
 
KD of 
125I-
Nle1-
Ang IV 
(nM) 
Bmax of 
125I-Nle1-
Ang IV 
(pmol 125I-
Nle1-Ang 
IV/pmol 
protein) 
KI of Nle1-
Ang IV 
(nM) 
KI of Ang 
IV (nM) 
1 (Cyto) Monomer 0.03 ± 0.01 * 
0.01 ± 0.02 
* No detectable binding 
2 (JxM,D1-3) Dimer 0.89 ± 0.11 * 0.91 ± 0.08 
0.63 ± 
0.07 
0.87 ± 
0.16 1.4 ± 0.3 16 ± 2.3 
3 (D1-2) Dimer 0.92 ± 0.09 * 0.89 ± 0.17 
0.57 ± 
0.12 
0.95 ± 
0.09 1.2 ± 0.4 16 ± 1.8 
4 (D3-4) Dimer 1.04 ± 0.18 * 1.02 ± 0.17 No detectable binding 
5 (D4) Dimer 0.98 ± 0.15 * 1.06 ± 0.11 No detectable binding 
6 (JxM,D1-4) Dimer 1.98 ± 0.04 
1.12 ± 0.18 
# 
0.72 ± 
0.09 
1.08 ± 
0.05 1.3 ± 0.3 17 ± 1.2 
7 (F/A, D1-4) Dimer 2.03 ± 0.07 
0.98 ± 0.09 
# 
0.78 ± 
0.14 
0.94 ± 
0.08 1.5 ± 0.2 16 ± 0.8 
8 (D1-4) Dimer 2.02 ± 0.06 
1.09 ± 0.15 
# 
0.76 ± 
0.08 
1.09 ± 
0.08 1.4 ± 0.2 17 ± 1.4 
 
 
* p < 0.001 compared to construct 6 
# p < 0.001 compared to in the absence of Ang IV 
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Table 2 Kinetic Constants  
 
Construct 
(aa residues) 
Km for 
MCA 
(µM) 
n = 3 
Kcat 
For MCA 
(s-1) 
n = 3 
Km for 
MCA 
with 1 
mM DTT 
(µM) 
n = 3 
Kcat 
For MCA 
with 1 
mM DTT 
(s-1) 
n = 3 
Ki Ang 
IV (nM) 
n = 3 
Ki LVV-
H7 (nM) 
n = 3 
Ki 
Amastatin 
(µM) 
n = 3 
Ki 
Bestatin 
(µM) 
n = 3 
2 (JxM,D1-3) 35.2 ± 3.0 
0.29 ± 
0.05 * 
33.0 ± 
2.0 * 
0.22 ± 
0.09 * 113 ± 3.7 859 ± 32 1.2 ± 0.12 222 ± 8.2 
3 (D1-2) 36.7 ± 1.2 
0.33 ± 
0.03 * 
34.5 ± 
1.8 * 
0.34 ± 
0.06 * 113 ± 3.3 857 ± 29 1.3 ± 0.11 225 ± 7.6 
6 (JxM,D1-4) 39.7 ± 0.82 
14.1 ± 
0.52 
25.7 ± 
0.73 ## 
21.6 ± 
1.6 ## 117 ± 2.3 847 ± 22 1.5 ± 0.09 233 ± 7.5 
7 (F/A, D1-4) 38.8 ± 2.3 
15.2 ± 
0.97 
26.1 ± 
0.82 ## 
22.0 ± 
2.2 ## 117 ± 2.8 849 ± 17 1.4 ± 0.08 231 ± 6.3 
8 (D1-4) 38.9 ± 2.0 
14.7 ± 
0.87 
26.1 ± 
0.75 ## 
22.4 ± 
2.0 ## 118 ± 3.2 851 ± 23 1.5 ± 0.08 232 ± 7.1 
3 (D1-2) mixed 
with + 5 (D4) 
35.8 ± 
1.5 
1.53 ± 
0.06 * 
30.3 ± 
1.44 # 
2.5 ± 
0.47 * 115 ± 2.8 852 ± 22 1.4 ± 0.11 228 ± 8.3 
 
* p < 0.001 compared to construct 6 
# p < 0.05 compared to in the absence of DTT  
## p < 0.001 compared to in the absence of DTT 
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